BusinessNatco Pharma Increases Investment in eGenesis to $25 Million
Natco Pharma is increasing its total investment in clinical-stage biotech company eGenesis to $24.7 million, up from the earlier $14 million plan. The Canadian subsidiary will invest $13.7 million and the US subsidiary $3 million. eGenesis develops porcine organ donors using gene-editing to address human organ shortages, focusing on kidney, liver, and heart transplants.
Hindu Business·2h ago·Hyderabad



